ReviewBiomarker research2025
Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy.
Review in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Personalized neoantigen mRNA vaccines for pancreatic cancer: the role of lipid nanoparticle delivery systems.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Pan-cancer analysis identifies immunoproteasome as the predominant survival-associated component of antigen processing machinery.Translational oncology · 2026Article
- Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy.Experimental & molecular medicine · 2026Review
- Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026Review
- A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations.Cancer research · 2026Article
- Integrated Transcriptomic Analysis Identifies a Six-Gene Prognostic Signature, RNA Editing Derived Neoantigens, and miRNA Regulatory Networks in Renal Cell Carcinoma.Iranian journal of medical sciences · 2026Article
- Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Rethinking Advanced Renal Cell Carcinoma: Integrative Genomics, Immunotherapy, and Molecular-Orthomolecular Strategies.Cancers · 2026Review
- SVNeoPP: A Workflow for Structural-Variant-Derived Neoantigen Prediction and Prioritization Using Multi-Omics Data.Biology · 2026Article
- Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1.Discover oncology · 2026Review
- Recent advances in multimodal foundation model-enabled peptide screening and optimization for smart biomaterials and functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Review
- Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.Advanced drug delivery reviews · 2025Review
- Nanovaccines in gastrointestinal cancers.Frontiers in immunology · 2025Review
- NeoTImmuML: a machine learning-based prediction model for human tumor neoantigen immunogenicity.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neoantigens, which are tumor-specific peptides generated by malignant cells, can be presented to T cells to elicit immune responses. Owing to their tumor-specific properties, neoantigens have emerged as one of the most promising biomarkers and targets for cancer immunotherapy. Previous studies have demonstrated their capacity to mediate tumor-specific immune responses in targeting and eliminating tumor cells while preserving normal cellular function. Driven by advancements in high-throughput sequencing technologies, mass spectrometry, and artificial intelligence, researchers have developed a growing interest in establishing more accurate neoantigen prediction algorithms. Here, we presented a comprehensive review of integrated neoantigen prediction algorithms, encompassing task definition, theoretical developments, benchmark datasets, cutting-edge applications, and future research directions. We systematically evaluated recent advancements in neoantigen source characterization and prediction algorithms, with particular emphasis on innovative methods for HLA-peptide binding and TCR recognition developed. Additionally, we explored the cutting-edge applications of neoantigens in personalized cancer vaccine design and adoptive cell therapies. We delineated potential research directions and the future prospects for neoantigen-based therapies, including integrating multi-omics data to discover universal neoantigens, addressing algorithmic generalization challenges and diversifying neoantigen validation methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.